Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Derivative

Shareholders claim Allergan's directors cost the company $600 million in fines and boosted the value of their own stock options by pushing the company's flagship drug, Botox, for unapproved uses, in a derivative complaint in Los Angeles Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...